HIV Glasgow 2020
HIV Drug Therapy Glasgow 2020
October 5-8, 2020 | Virtual
Van Wyk J, et al. Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks (TANGO study). Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Oral presentation O441.
Thursday, October 8, 2020, 12:15 PM - 12:28 PM EST
Margolis D, et al. A combination of viral and participant factors influence virologic outcome to long-acting cabotegravir and rilpivirine: multivariable and baseline factor analyses across ATLAS, FLAIR, and ATLAS-2M phase III studies. Presented at HIV Drug Therapy Glasgow, October 5-8, 2020, Glasgow, UK. Oral Presentation O442.
Thursday, October 8, 2020, 12:28PM - 12:41 PM EST
Are you a US healthcare provider?
This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.
If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.
Connect With Our Medical Experts
Request a Scientific Discussion
Submit a request for additional information from a ViiV Medical Expert.
Report an Adverse Event
To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1‑877‑844‑8872 or FDA at 1‑800‑332‑1088 or www.fda.gov/medwatch